Abstract:Mumps vaccines are live attenuated viruses. They are known to vary in effectiveness, degree of attenuation and adverse event profile. However, the underlying reasons are poorly understood. We studied two closely related mumps vaccines which originate from the same attenuated Jeryl Lynn-5 strain but have different efficacies. Jeryl Lynn-Canine Kidney (JL-CK), produced on primary canine kidney cells, is less effective than RIT4385, which is produced on chicken embryo fibroblasts. JL-CK and RIT4385 could be distinguished by a number of in vitro and in vivo properties. JL-CK produced heterogeneous, generally smaller plaques than RIT4385, but gave 100-fold higher titres when grown in cells and showed a higher degree of hydrocephalus formation in neonatal rat brains. Sanger sequencing of JL-CK identified 14 regions of heterogeneity throughout the genome. Plaque purification of JL-CK demonstrated the presence of five different Jeryl Lynn-5 variants encompassing the 14 mutations. One JL-CK mutation was associated with a small plaque phenotype, the effects of the others in vitro or in vivo were less clear. Only 4% of the JL-CK population corresponded to the parental Jeryl Lynn-5 strain. Next generation sequencing of JL-CK and virus before and after growth in cell lines or neonatal rat brains showed that propagation in vitro or in vivo altered the population dramatically. Our findings indicate that growth of JL-CK in primary canine kidney cells resulted in the selection of a mixture of mumps virus variants that have different biological properties compared to the parent Jeryl Lynn-5 virus. We also report three previously unknown heterogenic regions within the N gene of the RIT4385 vaccine.

Development and biological properties of a new live attenuated mumps vaccine

Development of Improved Mumps Vaccine Candidates by Mutating Viral mRNA Cap Methyltransferase Sites in the Large Polymerase Protein

Establishment of an Efficient Reverse Genetic System of Mumps Virus S79 from Cloned DNA

Safety and immunogenicity of a live attenuated mumps vaccine: a phase I clinical trial.

Neurovirulence of mumps virus: intraspinal inoculation test in marmosets

Pathogenicity and Immunogenicity of Recombinant Methyltransferase-Defective Vesicular Stomatitis Virus

Immunogenicity of novel mumps vaccine candidates generated by genetic modification

Generation of a recombinant Oka varicella vaccine expressing mumps virus hemagglutinin-neuraminidase protein as a polyvalent live vaccine

Immunogenicity and Cross-Protection Efficacy of a Genotype F-Derived Attenuated Virus Vaccine Candidate against Mumps Virus in Mice

Novel polyvalent live vaccine against varicella-zoster and mumps virus infections

Identification and development of a promising novel mumps vaccine candidate strain

Gene-specific contributions to mumps virus neurovirulence and neuroattenuation

A highly efficacious live attenuated mumps virus–based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike

In vitro and in vivo growth alter the population dynamic and properties of a Jeryl Lynn mumps vaccine

Preclinical Evaluation of the Safety and Pathogenicity of a Live Attenuated Recombinant Influenza A/H7N9 Seed Strain and Corresponding MF59-adjuvanted Split Vaccine

The Brucella Melitensis M5-90ΔmanB Live Vaccine Candidate is Safer Than M5-90 and Confers Protection Against Wild-Type Challenge in BALB/c Mice.

A Safety and Immunogenicity Study of a Novel Subunit Plague Vaccine in Cynomolgus Macaques

Accumulation of defective interfering viral particles in only a few passages in Vero cells attenuates mumps virus neurovirulence

Identification of genetic mutations associated with attenuation and changes in tropism of Urabe mumps virus

Neurovirulence safety testing of mumps vaccines--historical perspective and current status

Infection of mice, ferrets, and rhesus macaques with a clinical mumps virus isolate